Tauro-β-muricholic acid sodium
Names
[ CAS No. ]:
145022-92-0
[ Name ]:
Tauro-β-muricholic acid sodium
Biological Activity
[Description]:
Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3].
[Related Catalog]:
[Target]
IC50: 40 μM (FXR)[1]
[In Vitro]
T-βMCA sodium inhibits FXR reporter activity in the CRC cell line HT29 (EC50 ~10 μM)[3]. T-βMCA sodium dose-dependently increases WNT signaling in HT29 and HCT116 cells[3]. T-βMCA sodium induces proliferation and DNA damage in Lgr5+ cells[3].
[In Vivo]
T-βMCA sodium (400 mg/kg; i.g.; twice a week; for 6 weeks) can effectively recapitulate the ability of HFD to promote CRC progression[3]. T-βMCA sodium treatment also significantly increases levels of serum cytokines, including IFN-γ, IL-6, and IL-17[3]. Animal Model: APCmin/+ mice[3] Dosage: 400 mg/kg Administration: Oral gavage; twice a week; for 6 weeks Result: Markedly decreased intestinal integrity and accelerated tumor growth in the intestine and colon.
[References]
Chemical & Physical Properties
[ Molecular Formula ]:
C26H44NNaO7S
[ Molecular Weight ]:
537.68
[ Storage condition ]:
-20°C